AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Clover Health Investments, Corp Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) filed an 8-K disclosing its ninth one-month extension to complete a business combination. The Board moved the deadline, known as the “Business Combination Period,� from 5 Aug 2025 to 5 Sep 2025.

To effect the extension, sponsor CGC II Sponsor LLC will advance $250,000 under an unsecured promissory note that permits borrowings up to $2.4 million. The funds will be deposited into the IPO trust account as required by the company’s amended memorandum and articles.

This is the 9th of 12 permissible monthly extensions; no additional financial results, target identification, or other material transactions were reported.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) ha presentato un modulo 8-K comunicando la sua nona estensione mensile per completare una fusione aziendale. Il Consiglio ha spostato la scadenza, nota come “Periodo di Combinazione Aziendale,� dal 5 agosto 2025 al 5 settembre 2025.

Per effettuare l'estensione, lo sponsor CGC II Sponsor LLC anticiperà 250.000 dollari tramite una nota di debito non garantita che consente prestiti fino a 2,4 milioni di dollari. I fondi saranno depositati nel conto fiduciario dell'IPO come previsto dal memorandum e dagli articoli modificati della società.

Questa è la 9ª delle 12 estensioni mensili consentite; non sono stati riportati ulteriori risultati finanziari, identificazioni di obiettivi o altre transazioni rilevanti.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) presentó un formulario 8-K anunciando su novena prórroga mensual para completar una combinación de negocios. La Junta movió la fecha límite, conocida como el “Período de Combinación de Negocios,� del 5 de agosto de 2025 al 5 de septiembre de 2025.

Para efectuar la prórroga, el patrocinador CGC II Sponsor LLC adelantará 250,000 dólares bajo un pagaré no garantizado que permite préstamos hasta 2.4 millones de dólares. Los fondos serán depositados en la cuenta fiduciaria de la OPI según lo requerido por el memorándum y los estatutos modificados de la empresa.

Esta es la 9ª de 12 prórrogas mensuales permitidas; no se reportaron resultados financieros adicionales, identificación de objetivos ni otras transacciones materiales.

Cartesian Growth Corporation II (나스ë‹�: RENE/RENEU/RENEW)ëŠ� 사업 ê²°í•© 완료ë¥� 위한 아홉 번째 1개월 연장ì—� 대í•� 8-K 보고서를 제출했습니다. ì´ì‚¬íšŒëŠ” ‘사ì—� ê²°í•© 기간â€� 마ê°ì¼ì„ 2025ë…� 8ì›� 5ì¼ì—ì„� 2025ë…� 9ì›� 5ì¼ë¡œ 연기했습니다.

연장 조치ë¥� 위해 스í°ì„œì¸ CGC II Sponsor LLCëŠ� 최대 240ë§� 달러까지 차입ì� 가능한 무담ë³� 약ì†ì–´ìŒìœ¼ë¡œ 25ë§� 달러ë¥� 선지급할 예정입니ë‹�. ì� ìžê¸ˆì€ 회사ì� 수정ë� ì •ê´€ê³� 메모랜ë¤ì—� ë”°ë¼ IPO ì‹ íƒ ê³„ì¢Œì—� 입금ë©ë‹ˆë‹�.

ì´ë²ˆì� 허용ë� 12íš� ì¤� 9번째 월별 연장입니ë‹�; 추가 재무 실ì , 목표 ì‹ë³„ ë˜ëŠ” 기타 중요í•� 거래ëŠ� ë³´ê³ ë˜ì§€ 않았습니ë‹�.

Cartesian Growth Corporation II (Nasdaq : RENE/RENEU/RENEW) a déposé un formulaire 8-K annonçant sa neuvième prolongation d’un mois pour finaliser une opération de fusion. Le conseil d’administration a repoussé la date limite, appelée « Période de combinaison d’entreprise », du 5 août 2025 au 5 septembre 2025.

Pour effectuer cette prolongation, le sponsor CGC II Sponsor LLC avancera 250 000 dollars via un billet à ordre non garanti autorisant des emprunts jusqu’� 2,4 millions de dollars. Les fonds seront déposés sur le compte séquestre de l’IPO conformément au mémorandum et aux statuts modifiés de la société.

Il s’agit de la 9ème des 12 prolongations mensuelles autorisées ; aucun résultat financier supplémentaire, identification de cible ou autre transaction importante n’a été rapporté.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) hat ein 8-K eingereicht und seine neunte einmonatige Verlängerung zur Durchführung einer Unternehmenszusammenführung bekannt gegeben. Der Vorstand hat die Frist, bekannt als „Business Combination Period�, vom 5. August 2025 auf den 5. September 2025 verschoben.

Zur Umsetzung der Verlängerung wird der Sponsor CGC II Sponsor LLC 250.000 US-Dollar mittels eines ungesicherten Schuldscheindarlehens vorschießen, das Darlehen bis zu 2,4 Millionen US-Dollar erlaubt. Die Mittel werden auf das IPO-Treuhandkonto eingezahlt, wie es im geänderten Gesellschaftsvertrag der Firma vorgeschrieben ist.

Dies ist die 9. von 12 zulässigen monatlichen Verlängerungen; es wurden keine weiteren Finanzergebnisse, Zielidentifikationen oder sonstige wesentliche Transaktionen gemeldet.

Positive
  • Sponsor advances $250,000 to fund the trust, signaling ongoing financial support.
  • Trust account remains intact, preserving redemption value for public shareholders.
Negative
  • Ninth extension highlights continued inability to secure a merger target, increasing deal uncertainty.
  • Additional borrowing under the $2.4 million note raises leverage ahead of any future transaction.

Insights

TL;DR � Ninth extension keeps SPAC alive but signals difficulty closing a deal; sponsor support limits immediate redemption risk.

Another one-month extension to 5 Sep 2025 indicates CGC II has yet to secure a definitive merger agreement. The sponsor’s $250k deposit demonstrates continued financial backing, protecting the trust value and meeting charter requirements. However, with only three monthly extensions left, time pressure rises and potential targets gain negotiating leverage. Overall impact is neutral: cash safety maintained, but strategic uncertainty persists.

TL;DR � Repeated deadline pushes heighten execution risk; growing sponsor loan increases leverage against future proceeds.

The ninth consecutive extension underscores prolonged deal sourcing challenges, raising the probability of liquidation or shareholder fatigue. Each draw on the unsecured note—now at least $250k—adds liabilities senior to ordinary shareholders upon closing. With only three extensions remaining, investors should monitor note balance growth and any shift in sponsor commitment. From a risk viewpoint, the filing leans negative because timeline slippage and incremental debt can erode eventual transaction economics.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) ha presentato un modulo 8-K comunicando la sua nona estensione mensile per completare una fusione aziendale. Il Consiglio ha spostato la scadenza, nota come “Periodo di Combinazione Aziendale,� dal 5 agosto 2025 al 5 settembre 2025.

Per effettuare l'estensione, lo sponsor CGC II Sponsor LLC anticiperà 250.000 dollari tramite una nota di debito non garantita che consente prestiti fino a 2,4 milioni di dollari. I fondi saranno depositati nel conto fiduciario dell'IPO come previsto dal memorandum e dagli articoli modificati della società.

Questa è la 9ª delle 12 estensioni mensili consentite; non sono stati riportati ulteriori risultati finanziari, identificazioni di obiettivi o altre transazioni rilevanti.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) presentó un formulario 8-K anunciando su novena prórroga mensual para completar una combinación de negocios. La Junta movió la fecha límite, conocida como el “Período de Combinación de Negocios,� del 5 de agosto de 2025 al 5 de septiembre de 2025.

Para efectuar la prórroga, el patrocinador CGC II Sponsor LLC adelantará 250,000 dólares bajo un pagaré no garantizado que permite préstamos hasta 2.4 millones de dólares. Los fondos serán depositados en la cuenta fiduciaria de la OPI según lo requerido por el memorándum y los estatutos modificados de la empresa.

Esta es la 9ª de 12 prórrogas mensuales permitidas; no se reportaron resultados financieros adicionales, identificación de objetivos ni otras transacciones materiales.

Cartesian Growth Corporation II (나스ë‹�: RENE/RENEU/RENEW)ëŠ� 사업 ê²°í•© 완료ë¥� 위한 아홉 번째 1개월 연장ì—� 대í•� 8-K 보고서를 제출했습니다. ì´ì‚¬íšŒëŠ” ‘사ì—� ê²°í•© 기간â€� 마ê°ì¼ì„ 2025ë…� 8ì›� 5ì¼ì—ì„� 2025ë…� 9ì›� 5ì¼ë¡œ 연기했습니다.

연장 조치ë¥� 위해 스í°ì„œì¸ CGC II Sponsor LLCëŠ� 최대 240ë§� 달러까지 차입ì� 가능한 무담ë³� 약ì†ì–´ìŒìœ¼ë¡œ 25ë§� 달러ë¥� 선지급할 예정입니ë‹�. ì� ìžê¸ˆì€ 회사ì� 수정ë� ì •ê´€ê³� 메모랜ë¤ì—� ë”°ë¼ IPO ì‹ íƒ ê³„ì¢Œì—� 입금ë©ë‹ˆë‹�.

ì´ë²ˆì� 허용ë� 12íš� ì¤� 9번째 월별 연장입니ë‹�; 추가 재무 실ì , 목표 ì‹ë³„ ë˜ëŠ” 기타 중요í•� 거래ëŠ� ë³´ê³ ë˜ì§€ 않았습니ë‹�.

Cartesian Growth Corporation II (Nasdaq : RENE/RENEU/RENEW) a déposé un formulaire 8-K annonçant sa neuvième prolongation d’un mois pour finaliser une opération de fusion. Le conseil d’administration a repoussé la date limite, appelée « Période de combinaison d’entreprise », du 5 août 2025 au 5 septembre 2025.

Pour effectuer cette prolongation, le sponsor CGC II Sponsor LLC avancera 250 000 dollars via un billet à ordre non garanti autorisant des emprunts jusqu’� 2,4 millions de dollars. Les fonds seront déposés sur le compte séquestre de l’IPO conformément au mémorandum et aux statuts modifiés de la société.

Il s’agit de la 9ème des 12 prolongations mensuelles autorisées ; aucun résultat financier supplémentaire, identification de cible ou autre transaction importante n’a été rapporté.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) hat ein 8-K eingereicht und seine neunte einmonatige Verlängerung zur Durchführung einer Unternehmenszusammenführung bekannt gegeben. Der Vorstand hat die Frist, bekannt als „Business Combination Period�, vom 5. August 2025 auf den 5. September 2025 verschoben.

Zur Umsetzung der Verlängerung wird der Sponsor CGC II Sponsor LLC 250.000 US-Dollar mittels eines ungesicherten Schuldscheindarlehens vorschießen, das Darlehen bis zu 2,4 Millionen US-Dollar erlaubt. Die Mittel werden auf das IPO-Treuhandkonto eingezahlt, wie es im geänderten Gesellschaftsvertrag der Firma vorgeschrieben ist.

Dies ist die 9. von 12 zulässigen monatlichen Verlängerungen; es wurden keine weiteren Finanzergebnisse, Zielidentifikationen oder sonstige wesentliche Transaktionen gemeldet.

FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702025-08-052025-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

CLOVER HEALTH INVESTMENTS, CORP.

(Exact name of Registrant as Specified in Its Charter)

Delaware
001-3925298-1515192
(State or Other Jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
Identification No.)
Not Applicable(1)
 Not Applicable(1)
(Address of Principal Executive Offices)(Zip Code)
Not Applicable(1)
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:

Trading
Title of each class
Symbol(s)
Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
(1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: [email protected], or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801.





Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, Clover Health Investments, Corp. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information set forth in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.

(d) List of Exhibits

Exhibit No.Description
99.1
Press release dated August 5, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Clover Health Investments, Corp.
Date:August 5, 2025By:/s/ Peter Kuipers
Name:Peter Kuipers
Title:Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

FAQ

Why did RENE/RENEW file this Form 8-K?

The company disclosed approval of its ninth one-month extension to complete a business combination and the related $250,000 sponsor deposit.

What is the new business-combination deadline for Cartesian Growth Corporation II?

The deadline was extended to September 5, 2025.

How much money is being added to the trust account?

$250,000 will be deposited by the sponsor under an unsecured promissory note.

How many extensions remain under the Articles?

Three one-month extensions remain; this was the 9th of 12 allowable extensions.

Does the filing mention any merger target or financial results?

No. The 8-K reports only the extension and related funding; no target or earnings data were provided.
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

CLOV Latest News

CLOV Latest SEC Filings

CLOV Stock Data

1.41B
400.32M
3.77%
27.27%
7.11%
Healthcare Plans
Hospital & Medical Service Plans
United States
JERSEY CITY